Intellia Therapeutics stock is coming off a very heavy five year decline, yet the current valuation checks still suggest a mixed picture rather than a clear bargain.

• Over the past five years, Intellia Therapeutics has delivered a share price decline of about 93%, which means long term holders have seen most of their capital eroded.
• Future value for shareholders may hinge on whether Intellia Therapeutics can turn its R&D pipeline into commercially viable therapies while managing the risks that come with high ongoing development spend and uncertain cash flows.
• The company passes roughly half of Simply Wall St's checks, scoring 3 out of 6 on the value score, which points to a stock that looks neither clearly cheap nor clearly expensive on the broader tests.

The issue now is whether the current price offers enough upside potential to compensate for the risks that Intellia Therapeutics shareholders have already experienced.

Does Intellia Therapeutics Look Pricey on Sales?

For a business like Intellia Therapeutics that is still loss making and focused on its pipeline, the P/S ratio is often used as a quick way to judge how heavily the market values each dollar of current revenue.

Intellia Therapeutics trades on a P/S of about 23.2x, which is roughly double the broader biotech industry average of 11.5x and below the peer group average of 34.5x. That places the stock at a premium to the typical biotech company on sales, even though it is not at the very top end of its closer peer set.

The fair P/S ratio from the model is just 0.1x, which is very small compared with the current 23.2x. This gap suggests the framework is heavily penalising Intellia Therapeutics for its losses, risk profile and the quality of current revenue. As a result, the fair value output looks more like a warning flag than a precise target.

Overall, Intellia Therapeutics screens as overvalued on a sales based multiple.

The Intellia Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Intellia Therapeutics valuation puzzle leaves off and spell out which combinations of future growth, margins and earnings would need to occur for the stock to be worth materially more or less than today’s price, based on views shared on the Community page. Rather than relying on a single multiple or model output, each one lays out the assumptions behind its fair value so you can compare them with results as new data is reported.

One of the top community narratives on Intellia Therapeutics: 59% undervalued

"Improving financial discipline, as evidenced by successful restructuring, declining GAAP operating expenses, and a robust cash runway into the first half of 2027, enables Intellia to absorb increased R&D investment…"

Do you think there's more to the story for Intellia Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

For Intellia Therapeutics, the current picture points to an overvalued stock on sales-based multiples, with a very wide gap between the modeled fair P/S and where the market currently prices the shares. That mismatch reflects how heavily the framework discounts ongoing losses and execution risk. The mixed valuation checks suggest focusing less on whether the stock looks optically cheap and more on whether Intellia Therapeutics can turn its R&D pipeline into durable, higher quality revenue. The key debate from here is whether future clinical and commercial progress will ultimately justify today’s premium pricing on sales.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.